Acquisition Enhances Ion Channel Discovery Services

Oct 29 2014

ChanTestCharles River is pleased to announce the acquisition of ChanTest, a market leader in ion channel drug discovery and associated in vitro safety testing. The addition of this world-class organization to our Discovery Services portfolio complements our existing ion channel capabilities, which are located at our UK-based discovery services business (BioFocus), and broadens our scientific depth and the services we can provide to our clients in their mission to discover and develop new medicines.

Located in Cleveland, Ohio, ChanTest is a trusted leader in the early functional screens for profiling drug candidates or ranking within profiles during the drug discovery process, as well as in vitro GLP services for cardiac risk assessment.

Since its inception in 1998, ChanTest has tested 30,000+ compounds for more than 300 global pharmaceutical and biotech companies, and ChanTest scientists have published 300+ papers in peer-reviewed journals. Today, ChanTest leads the next major advance in ion channel services. The ChanTest Cell Line Catalogue can be mixed and matched as Ion Channel Panels–FDA Critical Path tools for efficiently moving drug candidates through development. The ChanTest Ion Channel Panels can be arranged according to tissue, therapeutic area or ion channel class.

For more information, please contact us at 1.877.CRIVER.1 or askcharlesriver@crl.com.